CYP3A4 drug interactions: Correlation of 10 in vitro probe substrates

British Journal of Clinical Pharmacology

Volumn 48, Issue 5, 1999, Pages 716-727

  Kenworthy, K E ^a,b   Bloomer, J C ^b   Clarke, S E ^b   Houston, J B ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Allostery; CYP3A4; Cytochrome P450 inhibition; In vitro probes

Indexed keywords

ASTEMIZOLE; BENZYLOXYRESORUFIN; BUDESONIDE; CAFFEINE; CISAPRIDE; CLOTRIMAZOLE; CLOZAPINE; CYCLOSPORIN; CYTOCHROME P450 3A4; CYTOCHROME P450 ISOENZYME; DEXTROMETHORPHAN; DIAZEPAM; DIGITOXIN; DISOPYRAMIDE; ERYTHROMYCIN; ETHIONAMIDE; ETHOXYRESORUFIN; FLUCONAZOLE; GENTAMICIN; HALOPERIDOL; IBUPROFEN; ITRACONAZOLE; MIDAZOLAM; NIFEDIPINE; RECOMBINANT ENZYME; RESORUFIN DERIVATIVE; TERFENADINE; TESTOSTERONE; TRIAZOLAM; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; CLUSTER ANALYSIS; CONTROLLED STUDY; DEALKYLATION; DEMETHYLATION; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG OXIDATION; DRUG POTENCY; DRUG PROTEIN BINDING; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME SUBSTRATE COMPLEX; MICHAELIS CONSTANT; PRIORITY JOURNAL;

CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; HUMANS; KINETICS; MIXED FUNCTION OXYGENASES; PHARMACEUTICAL PREPARATIONS; RECOMBINANT PROTEINS;

EID: 0032735988     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1999.00073.x     Document Type: Article

References (36)

1. 1 Wrighton SA, Vandenbranden M, Stevens JC, Shipley LA, Ring BJ. In vitro methods for assessing human hepatic drug metabolism: Their use in drug development. Drug Metab Rev 1993; 25: 453-484.
2. 2 Watkins PB, Wrighton SA, Maurel P, et al. Identification of an inducible form of cytochrome P450 in human liver. Proc Natl Acad Sci 1985; 82: 6310-6314.
3. 3 Guengerich FP, Martin MV, Beaune PH, Kremers P, Wolff T, Waxman DJ. Characterisation of rat and human liver microsomal cytochrome P450 forms involved in nifedipine oxidation, a prototype genetic polymorphism in oxidative drug metabolism. J Biol Chem 1986; 261: 5051-5060.
4. 4 Kronbach T, Mathys D, Umeno M, Gonzalez FJ, Meyer UA. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol Pharmacol 1989; 36: 89-96.
5. 5 Andersson T, Miners JO, Veronese ME, Birkett DJ. Diazepam metabolism by human liver microsomes is mediated by both S-mephenytoin hydroxylase and CYP3A isofonns. Br J Clin Pharmacol 1994; 38: 131-137.
6. 6 Waxman DJ, Attisano C, Guengerich FP, Lapenson DP. Human liver microsomal steroid metabolism: Identification of the major microsomal steroid hormone 6β-hydroxylase cytochrome P450 enzyme. Arch Biochem Biophys 1988; 263: 424-436.
7. 7 Rodrigues AD, Mulford DJ, Lee RD, et al. In vitro metabolism of terfenadine by a purified recombinant fusion protein containing cytochrome P4503A4 and NADPII-P450 reductase. Drug Metab Dispos 1995; 23: 765-775.
8. 8 Pichard L, Fabre I, Fabre G, et al. Cyclosporin A drug interactions: Screening for inducers and inhibitors of cytochrome P450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. Drug Metab Dispos 1990; 18: 595-606.
9. 9 Watkins PB. Noninvasive tests of CYP3A enzymes. Pharmacogenetics 1994; 4: 171-184.
10. 10 Thummel KE, Wilkinson GR. In vitro and in vivo drug interaction involving human CYP3A. Ann Rev Pharmacol Toxicol 1998; 38: 389-430.
11. 11 Watkins PG, Hamilton TA, Annesley TM, Ellis CN, Kolars JC, Voorhees JJ. The erythromycin breath test as a predictor of cyclosporin blood levels. Clin Pharmacol Ther 1990; 48: 120-129.
12. 12 Turgeon DK, Normolle DP, Leichtman AB, Annesley TM, Smith DE, Watkins PB. Erythromycin breath test predicts oral clearance of cyclosporin in kidney transplant recipients. Clin Pharmacol Ther 1992; 52: 471-478.
13. 13 Hunt CM, Watkins PG, Saenger P, Stave GM, Barlascini N. Heterogeneity of CYP3A isoforms metabolising erythromycin and cortisol. Clin Pharmacol Ther 1992; 51: 18-23.
14. 14 Watkins PB, Turgeon DK, Saenger P, et al. Comparison of urinary 6β-cortisol and the erythromycin breath test as measures of hepatic P450IIIA (CYP3A) activity. Clin Pharmacol Ther 1992; 52: 265-273.
15. 15 Kinirons MT, O'Shea D, Downing TE, et al. Absence of correlations among three putative in vivo probes of human cytochrome P4503A activity in young healthy men. Clin Pharmacol Ther 1993; 54: 621-629.
16. 16 Kinirons MT, O'Shea D, Groopman JD, Thummel KE, Wood AJJ, Wilkinson GR. Route of administration does not explain the lack of correlation between putative in vivo probes of cytochrome P4503A. Br J Clin Pharmacol 1994; 37: 501P.
17. 17 Krivoruk Y, Kinirons MT, Wood AJJ, Wood M. Metabolism of cytochrome P4503A substrates in vivo administered by the same route: Lack of correlation between alfentanil clearance and erythromycin breath test. Clin Pharmacol Ther 1994; 56: 608-614.
18. 18 Lown KS, Thummel KE, Benedict PE, Shen DD, Turgeon DK. The erythromycin breath test predicts the clearance of midazolam. Clin Pharmacol Ther 1995; 57: 16-24.
19. 19 Stein CM, Kinirons MT, Pincus T, Wilkinson GR, Wood AJJ. Comparison of the dapsone recovery ratio and the erythromycin breath test as in vivo probes of CYP3A activity in patients with rheumatoid arthritis receiving cyclosporin. Clin Pharmacol Ther 1996; 59: 47-51.
20. 20 Lown KS, Kolars JC, Thummel KE, Barnett JL, Kunze KL. Inter-patient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel: Lack of prediction by the erythromycin breath test. Drug Metab Dispos 1994; 22: 947-955.
21. 21 Ueng Y-F, Kuwabara T, Chun Y-J, Guengerich FP. Cooperatively in oxidations catalysed by cytochrome P450 3A4. Biochemistry 1997; 36: 370-381.
22. 22 Wang RW, Newton DJ, Scheri TD, Lu AYH. Human cytochrome P450 3A4-catalysed testosterone 6β-hydroxylation and erythromycin N-demethylation: Competition during catalysis. Drug Metab Dispos 1997; 25: 502-507.
23. 23 Bensoussan C, Delaforge M, Mansuy D. Particular ability of cytochrome P450, 3A to form inhibitory P450 iron-metabolite complexes upon metabolic oxidation of aminodrugs. Biochem Pharmacol 1995; 49: 591-602.
24. 24 Shou M, Grogan J, Mancewicz JA, et al. Activation of CYP3A4: Evidence for the simultaneous binding of two substrates in a cytochrome P450 active site. Biochemistry 1994; 33: 6450-6455.
25. 25 Korzekwa KR, Krishnamachary N, Shou M, et al. Evaluation of atypical cytochrome P450 kinetics with two-substrate models: Evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. Biochemistry 1998; 37: 4137-4147.
26. 26 Gorski JC, Jones DR, Wrighton SA, Hall SD. Characterisation of dextromethorphan N-demethylation by human liver microsomes: Contribution of the cytochrome P450, 3A subfamily. Biochem Pharmacol 1994a 48: 173-182.
27. 27 Von Moltke LL, Greenblatt DJ, Harmatz JS, et al. Triazolam biotransformanon by human liver microsomes in vitro: Effects of metabolic inhibitors and clinical conformation of a predicted interaction with ketoconazole. J Pharmacol Exp Ther 1996; 276: 370-379.
28. 28 Crespi CL, Miller VP, Penman BW. Microtiter plate assays for inhibition of human drug metabolising cytochromes P450. Anal Biochem 1997; 248: 188-190.
29. 29 Craig DA. The Cheng-Prusoff relationship: Something lost in the translation. Trends Pharmacol Sci 1993; 14: 89-91.
30. 30 Leff P, Dougall IG. Further concerns over Cheng-Prusoff analysis. Trends Pharm Sci 1993; 14: 110-112.
31. 31 Bourrie M, Meunier V, Berger Y, Fabre G. Cytochrome P450 inhibitors as a tool for the investigation of metabolic reactions catalysed by human liver microsomes. J Pharmacol Exp Ther 1996; 277: 321-332.
32. 32 Newton DJ, Wang RW, Lu AYH. Cytochrome P450 inhibitors: Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 1995; 23: 154-158.
33. 33 Gomez DY, Wacher VJ, Tomlanovich SJ, Herbert MF, Benet LZ. The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporin. Clin Pharmacol Ther 1995; 58: 15-29.
34. 34 Olkkola KT, Ahonen J, Neuvonen PJ. The effect of the systemic antimycotics, itraconazole and fluconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Anesth Analg 1996; 82; 511-516.
35. 35 Soons PA, Mulders TM, Uchida E, Schoemaker HC, Cohen AF, Breimer DD. Stereoselective pharmacokinetics of oral felodipine and nitrendipine in healthy subjects: Correlation with nifedipine pharmacokinetics. Eur J Clin Pharmacol 1993; 44: 163-169.
36. 36 Yun CH, Okerholm RA, Guengerich FP. Oxidation of the antihistaminic drug terfenadine in human liver microsomes: Role of cytochrome P450, 3A (4) in N-dealkylation and C-hydroxylation. Drug Metab Dispos 1993; 21: 403-409.